Read by QxMD icon Read

Mitraclip, percutaneous mitral valve

Cüneyt Toprak, Gökhan Kahveci, Alev Kılıçgedik, Cevat Kırma, Selçuk Pala, Mustafa Bulut, Cihangir Kaymaz, Nihal Özdemir, İbrahim Akın İzgi, Mehmet İnanır, Anıl Avcı, Ali Metin Esen
OBJECTIVE: Mitral valve regurgitation (MR) is the second most common heart valve disease in Europe. Without intervention, prognosis of severe symptomatic MR is poor. Percutaneous edge-to-edge mitral valve repair with MitraClip is a promising mitral regurgitation treatment technique in select, high-surgical-risk patients. The present objective was to describe the experience of a single center with MitraClip use in a high-risk series in Turkey. METHODS: Between May 2013 and September 2014, 28 high-surgical-risk patients with MR of at least grade 3+ and mean EuroSCORE of 26% underwent MitraClip implantation at our institution...
October 2016: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
Richard Cheng, Emily Tat, Robert J Siegel, Reza Arsanjani, Asma Hussaini, Moody Makar, Yukiko Mizutani, Alfredo Trento, Saibal Kar
AIMS: Mitral annular calcification (MAC) negatively influences outcomes in surgical mitral valve (MV) repair for mitral regurgitation (MR). However, there are no data on whether MAC impacts on outcomes of MitraClip percutaneous MV edge-to-edge repair. This study sought to investigate whether the presence of MAC impacts on the procedural success and durability of percutaneous transcatheter repair of MR using the MitraClip. METHODS AND RESULTS: One hundred and seventy-three patients undergoing MitraClip repair for significant MR were studied...
October 20, 2016: EuroIntervention
Carsten Schwencke, Klaudija Bijuklic, Taoufik Ouarrak, Edith Lubos, Wolfgang Schillinger, Björn Plicht, Holger Eggebrecht, Stephan Baldus, Gerhard Schymik, Peter Boekstegers, Rainer Hoffmann, Jochen Senges, Joachim Schofer
AIMS: The use of the MitraClip system has gained widespread acceptance for the treatment of patients with mitral regurgitation (MR) who are not suitable for the conventional surgery. This study sought to investigate the early and 1-year outcome after MitraClip therapy of patients with MR and cardiac comorbidities. METHODS AND RESULTS: Outcomes through 12-month follow-up of patients (n = 528) who underwent MitraClip implantation were obtained from the German transcatheter mitral valve interventions (TRAMI) registry...
October 17, 2016: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
Denise C Joffe, Thomas K Jones, Mark Reisman, Elizabeth Perpetua, Yuk Law, Andreas Schuler, G Burkhard Mackensen
We present the primary report of a paediatric patient who had placement of the MitraClip device for severe functional mitral regurgitation. The patient was a 14-year-old boy with symptomatic end-stage non-compaction type cardiomyopathy secondary to a mitochondrial cytopathy. He had severe mitral regurgitation, tricuspid valve regurgitation, a severely dilated LV with apical non-compaction, severe LV dysfunction and severe pulmonary hypertension. Despite optimal medical therapy he developed progressive symptoms of congestive heart failure and he was not a candidate for an assist device or cardiac transplantation...
October 10, 2016: EuroIntervention
Salvatore Scandura, Piera Capranzano, Anna Caggegi, Carmelo Grasso, Giuseppe Ronsivalle, Sarah Mangiafico, Yohei Ohno, Guilherme F Attizzani, Stefano Cannata, Sandra Giaquinta, Silvia Farruggio, Margherita Ministeri, Fabio Dipasqua, Anna M Pistritto, Sebastiano Immè, Davide Capodanno, Maria Elena Di Salvo, Corrado Tamburino
BACKGROUND: Although mitral regurgitation (MR) affects a relevant and increasing number of elderly, an optimal management of this high-risk population is challenging. METHODS AND RESULTS: The aim of this prospective, observational study was to compare one-year outcomes of MitraClip therapy in high surgical risk patients with moderate-to-severe or severe MR between patients aged <75 versus ≥75years. A total of 180 patients were included: 92 were <75years and 88 were ≥75years old...
September 24, 2016: International Journal of Cardiology
Merrill H Stewart, J Stephen Jenkins
BACKGROUND: Mitral regurgitation (MR) is the second leading cause of valvular heart disease in the United States behind aortic stenosis. The percutaneous repair of the mitral valve (MitraClip, Abbott, Inc.) has been approved in the United States since 2013 as an alternative to traditional mitral valve surgery. However, many questions are left unanswered about when to perform this procedure and whom to perform it on. METHODS: We reviewed major published literature on the MitraClip from 2003-2016 to help guide clinical decision-making...
2016: Ochsner Journal
Subhi J Al'Aref, Geoffrey Bergman, S Chiu Wong
Percutaneous repair of the mitral valve has been widely adopted for the treatment of primary, symptomatic severe mitral regurgitation in patients at prohibitive risk for surgical intervention. We present a case of an elderly female patient with moderate-to-severe mitral regurgitation who underwent MitraClip procedure, with postprocedural course remarkable for the development of right-to-left shunting and hypoxia, for which the patient underwent a percutaneous repair of the atrial septal defect with immediate recovery of oxygen saturation...
September 2016: Journal of Invasive Cardiology
Cristina Giannini, Francesca Fiorelli, Antonio Colombo, Marco De Carlo, Sara Hana Weisz, Eustachio Agricola, Cosmo Godino, Fausto Castriota, Paolo Golino, Anna Sonia Petronio
BACKGROUND: Percutaneous mitral valve repair (PMVR) is a new option for high risk patients with functional mitral regurgitation (FMR) and severely depressed left ventricular (LV) function who are not responding to optimal medical therapy. However patients with end stage heart failure have a high mortality rate despite MitraClip implantation. We sought to identify right ventricular (RV) echocardiographic predictors of outcome in a large cohort of patients with severe FMR and advanced heart failure in order to select the most appropriate candidate who could benefit from this treatment...
November 15, 2016: International Journal of Cardiology
Giovanni Benfari, Rajesh Dandale, Andrea Rossi, Francesco Onorati, Giacomo Mugnai, Flavio Ribichini, Pier L Temporelli, Corrado Vassanelli
Functional mitral regurgitation is a form of valve insufficiency in the presence of anatomically normal mitral valve. The cause of functional mitral regurgitation is left ventricular remodelling that tethers valve leaflet more apically decreasing their coaptation ability. Given the pathophysiologic relation between functional mitral regurgitation and ventricular dysfunction, the valve insufficiency has long been considered a surrogate of ventricular disease. Accordingly, all potential therapeutic strategies able to decrease functional mitral regurgitation have been associated with improved ventricular function...
November 2016: Journal of Cardiovascular Medicine
Carlos Cortés, Ignacio J Amat-Santos, Luis Nombela-Franco, Antonio J Muñoz-Garcia, Enrique Gutiérrez-Ibanes, José M De La Torre Hernandez, Juan G Córdoba-Soriano, Pilar Jimenez-Quevedo, José M Hernández-García, Ana Gonzalez-Mansilla, Javier Ruano, Jesús Jimenez-Mazuecos, Javier Castrodeza, Javier Tobar, Fabian Islas, Ana Revilla, Rishi Puri, Ana Puerto, Itziar Gómez, Josep Rodés-Cabau, José A San Román
OBJECTIVES: This study sought to analyze the clinical impact of the degree and improvement of mitral regurgitation in TAVR recipients, validate the main imaging determinants of this improvement, and assess the potential candidates for double valve repair with percutaneous techniques. BACKGROUND: Many patients with severe aortic stenosis present with concomitant mitral regurgitation (MR). Cardiac imaging plays a key role in identifying prognostic factors of MR persistence after transcatheter aortic valve replacement (TAVR) and for planning its treatment...
August 8, 2016: JACC. Cardiovascular Interventions
Aeshita Dwivedi, Alan Vainrib, Muhamed Saric
PURPOSE OF REVIEW: Functional mitral regurgitation (FMR) is a common complication of left ventricular dysfunction. It is now recognized as an important clinical entity and an independent predictor of poor prognosis in cardiomyopathy patients. In this review, we provide a comprehensive summary of the pathophysiology, latest imaging modalities, and diagnostic criteria for FMR. Additionally, we discuss the recent literature on the continuously evolving surgical and percutaneous treatment options...
September 2016: Current Opinion in Cardiology
Kyle Eudailey, Nadira Hamid, Rebecca T Hahn, Susheel Kodali, William Gray, Isaac George
With the advent of percutaneous valve interventions, the landscape for management of high-risk valve replacement and repair has changed dramatically. Transcatheter valve repair/replacement techniques can be used in conjunction with open surgery to facilitate a hybrid approach in patients with multivalve disease. We present a case of staged hybrid valve repair followed by surgical replacement for a high-risk patient with mitral regurgitation and aortic regurgitation. This case illustrates the effectiveness of the staged hybrid approach for high-risk patients with incomplete transcatheter options...
August 2016: Annals of Thoracic Surgery
Panagiotis Antiochos, Olivier Muller, Matthias Kirsch, Melissa Agostini, Salah Qanadli, Eric Eeckhout, Pierre Vogt, René Prêtre, Alain Delabays, Xavier Jeanrenaud, Pierre Monney
Mitral regurgitation (MR) is the most frequent valvular disease in industrialised countries. MR is classified as primary (mostly degenerative with valve prolapse) or secondary (mainly due to underlying ischemic heart disease resulting in deformation of the valve structure). Surgical repair represents the optimal treatment for severe primary MR, whereas the benefits of surgical correction of secondary MR are controversial. Over the past few years, transcatheter techniques have been developed to treat MR, such as the percutaneous edge-to-edge procedure (MitraClip)...
May 25, 2016: Revue Médicale Suisse
T Tichelbäcker, M Puls, C Jacobshagen, G Hasenfuß, W Schillinger, M Hünlich, M R Schroeter
BACKGROUND: Percutaneous mitral valve repair using MitraClip® (MC) is a well-established method for a subset of patients with severe mitral regurgitation (MR) and high risk for surgical intervention. Amplatzer® Cardiac Plug (ACP) occludes left atrial appendage and allows the discontinuation of oral anticoagulation and prevention of thromboembolic stroke. Due to the need for femoral and transseptal access in both procedures, a single approach could lead to minor risk of further complications and shorter cumulative intervention time...
October 1, 2016: International Journal of Cardiology
Cuneyt Toprak, Gokhan Kahveci, Alev Kilicgedik, Selcuk Pala, Cevat Kirma, Mehmet Mustafa Tabakci, Mehmet Inanir, Ali Metin Esen
BACKGROUND: The goal of this study was to determine changes in left atrial (LA) function with two-dimensional speckle tracking echocardiography (2DSTE) and real-time full-volume three-dimensional echocardiography (RT3DE) after percutaneous mitral valve repair with the MitraClip system. Furthermore, we investigated whether baseline and/or changes in LA function after MitraClip repair had any impact on prognosis. METHODS: A total of 25 consecutive patients (age: 57±12 years, 76% male) with moderate-to-severe or severe mitral regurgitation (MR) were included...
June 27, 2016: Echocardiography
Claire Kelley, Mohamad Lazkani, Jennifer Farah, Ashish Pershad
Mitral valve disease affects more than 4 million people in the United States. The gold standard of treatment in these patients is surgical repair or replacement of the valve with a prosthesis. The MitraClip (Abbott Vascular, Menlo Park, CA) is a new technology, which offers an alternative to open surgical repair or replacement via a minimally invasive route. We present an evidence-based clinical update that provides an overview of this technology as it relates to managing patients with significant mitral regurgitation...
May 2016: Indian Heart Journal
Ji-Na Yoon, Antonio H Frangieh, Adrian Attinger-Toller, Christiane Gruner, Felix C Tanner, Maurizio Taramasso, Roberto Corti, Thomas F Lüscher, Frank Ruschitzka, Dominique Bettex, Francesco Maisano, Oliver Gaemperli
BACKGROUND: Mitral regurgitation (MR) is one of the most common valvular diseases. Percu-taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir-culating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated. METHODS: A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu-rich...
2016: Cardiology Journal
Mikihiko Kudo, Hideyuki Shimizu
Minimally invasive cardiac surgery (MICS), first introduced in the 1990s, was originally performed via partial sternotomy, the subxyphoid approach, and right anterolateral thoracotomy. Over the past 20 years, MICS procedures have progressed from mere alternatives to standard full sternotomy to endoscope-assisted and then to totally endoscopic open-heart procedures. MICS has gained popularity among surgeons and patients; without sacrificing the safety level and durability of cardiac procedures equivalent to median sternotomy, refinement of MICS technologies has resulted in a decrease in length of hospital stay, less postoperative pain, faster patient recovery, and faster return to activities of normal daily living...
March 2016: Nihon Geka Gakkai Zasshi
Sameer Gafoor, Horst Sievert, Francesco Maisano, Stephan Baldus, Ulrich Schaefer, Joerg Hausleiter, Christian Butter, Gian Paolo Ussia, Volker Geist, Julian D Widder, Tiziano Moccetti, Wolfgang Schillinger, Olaf Franzen
AIMS: Gender has been an important factor in outcomes after mitral valve surgery; however, its effect on percutaneous mitral valve repair is not well known. We aimed to report the effect of gender on outcomes in a large European prospective, multicentre, non-randomised post-approval study of percutaneous mitral valve repair. METHODS AND RESULTS: Two hundred and five female and 362 male patients with significant mitral regurgitation underwent percutaneous repair at 14 European sites from October 2008 to April 2011...
June 12, 2016: EuroIntervention
Hidehiro Kaneko, Michael Neuss, Thomas Schau, Jens Weissenborn, Christian Butter
BACKGROUND: MitraClip (MC; Abbott Vascular, Menlo Park, CA, USA) is a treatment option for mitral regurgitation. Renal dysfunction is closely associated with cardiovascular disease. However, the influence of renal function in MC remains not fully understood. In this study, we aimed to clarify the association between renal function and MC. METHODS AND RESULTS: We examined 206 consecutive patients who underwent MC and divided patients into 3 groups according to estimated glomerular filtration rate (eGFR), normal eGFR (≥60mL/min/1...
May 26, 2016: Journal of Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"